

**Oklahoma Health Care Authority**  
**Drug Utilization Review Board**  
(DUR Board)  
**Meeting – February 8, 2012 @ 6:00 p.m.**

Oklahoma Health Care Authority  
2401 N.W. 23<sup>rd</sup> Street, Suite 1-A  
Oklahoma City, Oklahoma 73107  
Ponca Room (North Entrance)

---

**AGENDA**

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. **Call To Order**
  - A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. **Public Comment Forum**
  - A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
  - A. January 11, 2011 DUR Minutes – Vote
  - B. January 12, 2011 DUR Recommendation Memorandum

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

4. **Update on DUR / Medication Coverage Authorization Unit – See Appendix B.**
  - A. Retrospective Drug Utilization Review for October 2011
  - B. Medication Coverage Activity Audit for January 2012
  - C. Pharmacy Help Desk Activity Audit for January 2012

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman

5. **Action Item – Vote to Prior Authorize Select Prenatal Vitamins– See Appendix C.**
  - A. COP Recommendations

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

6. **Action Item – Vote to Prior Authorize Soliris<sup>®</sup> – See Appendix D.**
  - A. COP Recommendations

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

7. **Action Item – Vote to Prior Authorize Onfi<sup>™</sup> – See Appendix E.**
  - A. COP Recommendations

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

8. **Action Item – Annual Review of Erythropoietin Stimulating Agents – See Appendix F.**
- A. Current Authorization Criteria
  - B. Utilization Review
  - C. Prior Authorization Review
  - D. Market News and Updates
  - E. COP Recommendations

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman

9. **Action Item – Annual Review of Narcotic Analgesics and 30 Day Notice to Prior Authorize Abstral<sup>®</sup>, Lazanda<sup>®</sup>, Nucynta<sup>®</sup> ER, and Oxecta<sup>®</sup> – See Appendix G.**
- A. Current Authorization Criteria
  - B. Utilization Review
  - C. Prior Authorization Review
  - D. Hydrocodone Utilization
  - E. Suboxone<sup>®</sup> and Subutex<sup>®</sup> Review
  - F. Market News and Updates
  - G. COP Recommendations

Items to be presented by Dr. Sipols, Dr. Muchmore, Chairman

10. **30 Day Notice to Prior Authorize Xgeva<sup>®</sup> – See Appendix H.**
- A. Product Summary
  - B. COP Recommendations

Items to be presented by Dr. Moore, Dr. Muchmore, Chairman

11. **30 Day Notice to Prior Authorize Makena<sup>™</sup> – See Appendix I.**
- A. Product Summary
  - B. COP Recommendations
  - C. Product Details

Items to be presented by Dr. Sipols, Dr. Muchmore, Chairman

12. **Action Item – Questions Regarding Annual Review of Mozobil<sup>®</sup>, Nplate<sup>®</sup>, Arcalyst<sup>®</sup>, and Ilaris<sup>®</sup> – See Appendix J.**
- A. Current Authorization Criteria
  - B. Utilization Review
  - C. Market News and Updates
  - D. COP Recommendations

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman

13. **FDA and DEA Updates – See Appendix K.**
14. **Future Business**
- A. Annual Review Qutenza<sup>®</sup>
  - B. Annual Review of Miscellaneous Special Formulation Anti-Infectives
  - C. New Product Reviews
  - D. Medical Product Reviews
15. **Adjournment**